• Immunome, Inc. recently announced that data from RINGSIDE, its global Phase 3 randomized, placebo-controlled trial of varegacestat in progressing desmoid tumor patients, has been selected for oral presentation at the 2026 ASCO Annual Meeting, with a New Drug Application to the US FDA planned for the second quarter of 2026.
• This combination of scientific visibility at a premier oncology forum and a near-term regulatory filing highlights how Immunome is moving varegacestat toward a potential commercial inflection point in desmoid tumors.
• With this backdrop and the upcoming NDA submission for varegacestat, we now examine how the announcement shapes Immunome’s broader investment narrative.

AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Immunome's Investment Narrative?

For Immunome, the big-picture belief is that varegacestat can anchor a focused oncology platform despite ongoing losses and dilution. The new ASCO 2026 oral slot for the RINGSIDE Phase 3 data reinforces the near-term NDA submission as the key catalyst, rather than adding a new one, but it does tighten the spotlight on regulatory and commercial execution. With the company still burning cash after a large US$400,437,500 equity raise and not expected to reach profitability in the next few years, the thesis leans heavily on successful approval and uptake in desmoid tumors, followed by pipeline validation from assets like IM-1021. Recent share price strength and prior insider selling underline how sentiment can swing quickly if trial, FDA or funding expectations shift.

However, one issue in particular could catch new shareholders off guard.
Despite retreating, Immunome's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly US$29.50 to over US$173, highlighting wide disagreement. Set against today’s focus on the varegacestat NDA and cash burn, that spread shows why it can help to compare several perspectives before deciding how Immunome might fit in a portfolio.

Explore 3 other fair value estimates on Immunome - why the stock might be worth just $29.50!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immunome research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Immunome research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunome's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 56 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.